Access our on-demand webinar.
Inflammatory bowel disease (IBD) is a chronic disorder of the small intestine and/or colon. Current treatments are often ineffective, but developing new IBD drugs is challenging due to flawed interpretation of preclinical data interpretation.
Download this webinar to learn more about using global proteomic analysis and digital pathology with preclinical models to uncover predictive IBD biomarkers to improve the interpretation of preclinical study results and enhance translation to human disease.
Feature Inotiv speakers include Dr. Melissa M. Walker, Associate Director of Pharmacology – Gastrointestinal Inflammation, Dr. Daniel C. Liebler, Vice President for Platform Technologies, and Dr. Michelle Panzica, Fluorescent Imaging Scientist.
This webinar will discuss:
- Key features of live phase, critical IBD biomarkers, and histopathological disease parameters in the adoptive T cell transfer model.
- How global proteome analysis characterizes protein drug target systems and pathways that drive disease phenotypes and response to therapeutics.
- The use of digital pathology and artificial intelligence to analyze biomarker localization and treatment efficacy.
Complete the form to access the on-demand webinar today.
